Published January 12, 2018
Epigenetics is a stream of genetics that involves the genetic development of an organism, especially the activation and deactivation of genes without changing its gene expression. An epigenetic change is natural and also influences the factors such as lifestyle and age. In-depth research on epigenetics has discovered human disorders and diseases.
The Asia Pacific Epigenetic Market Segments Size & Growth:
The Asia Pacific Epigenetic Market is accounted for $4 billion in 2017 and expected to grow at a CAGR of 32% to reach $13.2 billion by 2024 during the forecast period 2018-2024. Major factors that are driving the market growth owing to the increase in a number of cases of cancer; rise in investments and funds, and emerging various applications. However, high cost for epigenetic therapies, misinterpretation of genetic data, and lack of reimbursement hinder the growth of the epigenetics market.
The Asia Pacific Epigenetic Market SegmentsShare:
The Asia PacificEpigenetic Market is categorized into by type product which consists of reagents, kits, enzymes, and instruments. Kits have the largest share due to the increased usage of kits in epigenetic techniques. On the basis of technology, the epigenetic market is segmented as RNA interference, DNA methylation, and histone modifications. Among all DNA methylation are expected to have high growth rate during the forecast period 2018-2024, because of increase in cancer cases and the ability of epigenetics to treat cancer cells.Biotechnology and contract research organization are leading in the epigenetic market among end users owing to the rise in technological advancements, research, and manufacturing of precision medicine.
On the basis of Geography, China is dominating the epigenetic market and the growth in the Asia Pacific is mainly attributed because of the increasing demand for personalized medicine and rise in cancer cases. Furthermore, India is witnessing the fastest growth during the forecast period, due to rising aging population, chronic diseases and investment in R&D research.
The Asia Pacific Epigenetic Market SegmentsTrends:
The Asia Pacific Epigenetic Research Report:
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2Porter’s five force analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.4 SWOT Analysis
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1.1 High cases of cancer
4.1.2 Increasing investments
4.1.3 Various applications
4.2.1Lack of reimbursement
4.3.1 Emerging markets offer profitable opportunities
4.4.1.Complexities in gene structure.
Chapter 5 Asia Pacific Epigenetic Market – By Product
Chapter 6 Asia Pacific Epigenetic Market – By Technology
6.1 RNA Interference
6.2 DNA Methylation
6.3 Histone Modifications
Chapter 7 Asia Pacific Epigenetic Market – By End-User
7.3 Contract Research Organisation.
Chapter 8 Asia PacificEpigenetic Market – By Geography
8.2 Asia Pacific
8.2.3. South Korea
8.2.5. Australia & New Zealand
8.2.6. Rest of APAC
Chapter 9 Asia Pacific Epigenetic Market – Company Profiles
9.4. Merck Millipore
9.5. Karus Therapeutics
9.8.Eisai Co. Ltd.
9.11.Gilead Sciences Inc.
Chapter 10 Asia PacificEpigenetic Market – Competitive Landscape
10.1.Market Share Analysis
10.2.Strategies Adopted by top companies
10.3.Mergers, Acquisitions, Collaborations & Agreements
Chapter 11 Market Insights
11.1. Industry Experts Insights
Chapter 12 Appendix
12.1 List of Tables
12.2 List of Figures